Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis

Purpose. Two BRAF(V600E) targeted therapies, dabrafenib and vemurafenib, have received US approval for treatment of metastatic melanoma in BRAF(V600E) patients, a mutation that affects ~50% of patients. We evaluated the cost-effectiveness of BRAF inhibitors and traditional chemotherapy for treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Shih, Vanessa, ten Ham, Renske M., Bui, Christine T., Tran, Dan N., Ting, Jie, Wilson, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478371/
https://www.ncbi.nlm.nih.gov/pubmed/26171248
http://dx.doi.org/10.1155/2015/505302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478371/
https://www.ncbi.nlm.nih.gov/pubmed/26171248
http://dx.doi.org/10.1155/2015/505302

Ejemplares similares